Nanofix (Human Coagulation Factor Ix)

Human coagulation factor IX participates in the intrinsic pathway of the coagulation cascade. Once administered, it binds to activated factor VIII on phospholipid surfaces, forming the tenase complex that activates factor X. This leads to thrombin generation and fibrin clot formation, correcting the clotting defect caused by factor IX deficiency.

The dose of Nanofix is individualized. A qualified prescriber determines the amount and frequency based on the patient’s factor IX activity level, severity of bleeding, body weight, and clinical situation. Dosing instructions are provided on the prescription and product label.

Safety data for Nanofix in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the uncertainties and consider alternative therapies when appropriate.

To request Nanofix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any required import documentation.

Nanofix provides human‑derived factor IX, similar in activity to recombinant factor IX concentrates. While recombinant products are virus‑inactivated and have a consistent purity profile, plasma‑derived products like Nanofix may offer comparable efficacy at a different cost structure. Choice depends on clinical guidelines, patient history, and local availability.

Nanofix must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Nanofix is given by intravenous infusion. The healthcare professional prepares the dose according to the prescription, administers it slowly through a suitable IV line, and monitors the patient for any immediate adverse reactions during and after the infusion.

The most serious risks include the development of inhibitors (antibodies) against factor IX, which can render treatment ineffective, and severe allergic reactions such as anaphylaxis. Thromboembolic events are also possible, especially if dosing exceeds recommended levels or when combined with other pro‑coagulant agents.

Nanofix is contraindicated in patients with known hypersensitivity to human coagulation factor IX or any excipients in the formulation. It should also be avoided in individuals with a history of severe inhibitor formation unless a specialist advises otherwise.